IL33 and preeclampsia: Available tools—such as biomarker measurement (troponins, ST2/IL-33, telomere length) or the identification of obstetric histories, including preeclampsia or gestational diabetes—enable the early detection of elevated CVR and the initiation of timely interventions to prevent adverse outcomes.